The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...